eMed refiles IPO, acquires TrilixeMed Technologies is moving ahead with plans to expand its portfolio of Internet-based products and services, fueled in large part by the prospect of a pending $46 million initial public offering. The Lexington,
eMed refiles IPO, acquires Trilix
eMed Technologies is moving ahead with plans to expand its portfolio of Internet-based products and services, fueled in large part by the prospect of a pending $46 million initial public offering. The Lexington, MA-based company originally filed for an IPO last August (PNN 9/99) but postponed the offering one month later, citing market volatility with regard to health-related IPOs (PNN 11/99). Apparently sensing a more positive climate on Wall Street these days, eMed refiled its IPO with the Securities and Exchange Commission Feb. 25.
In related news, eMed acquired Trilix Information Systems, a software company founded by several former Cemax-Icon engineers. Trilix, headquartered in Pleasanton, CA, provides integration technology that allows the exchange of information among different healthcare imaging and information systems, both within a hospitals network and via the Internet. The addition of Trilixs technology to eMeds image-management products and services should help facilitate an organizations move toward electronic medical records, providing clinicians with connectivity to diagnostic images, as well as to laboratory, pathology, and other diagnostic reports.
eMed also plans to make Trilixs interface technologies available to other vendors on an OEM basis. Trilix already has OEM relationships with Kodak and Canon, according to company sources. eMed acquired Trilix in a straight stock deal.
© 2000 Miller Freeman, Inc., a United News & Media company.
AI Mammography Platform Shows Promising Results for Detecting Subclinical Breast Cancer
October 3rd 2024Mean artificial intelligence (AI) scoring for breasts developing cancer was double that of contralateral breasts at initial biennial screening and was 16 times higher at the third biennial screening, according to a study involving over 116,000 women with no prior history of breast cancer.
FDA Clears Software for Enhancing CCTA Assessment of Atherosclerosis
October 1st 2024Through analysis of coronary computed tomography angiography (CCTA) images, the PlaqueIQ software provides quantification and classification of atherosclerosis, a common cause of myocardial infarction (MI) and ischemic stroke.